360 related articles for article (PubMed ID: 17397003)
1. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.
Mark KE; Corey L; Meng TC; Magaret AS; Huang ML; Selke S; Slade HB; Tyring SK; Warren T; Sacks SL; Leone P; Bergland VA; Wald A
J Infect Dis; 2007 May; 195(9):1324-31. PubMed ID: 17397003
[TBL] [Abstract][Full Text] [Related]
2. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
3. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
4. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
[TBL] [Abstract][Full Text] [Related]
5. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study.
Spruance SL; Tyring SK; Smith MH; Meng TC
J Infect Dis; 2001 Jul; 184(2):196-200. PubMed ID: 11424018
[TBL] [Abstract][Full Text] [Related]
6. Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men.
Kim HN; Meier A; Huang ML; Kuntz S; Selke S; Celum C; Corey L; Wald A
J Infect Dis; 2006 Aug; 194(4):420-7. PubMed ID: 16845624
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.
Wald A; Zeh J; Selke S; Warren T; Ryncarz AJ; Ashley R; Krieger JN; Corey L
N Engl J Med; 2000 Mar; 342(12):844-50. PubMed ID: 10727588
[TBL] [Abstract][Full Text] [Related]
8. Effect of resiquimod 0.01% gel on lesion healing and viral shedding when applied to genital herpes lesions.
Fife KH; Meng TC; Ferris DG; Liu P
Antimicrob Agents Chemother; 2008 Feb; 52(2):477-82. PubMed ID: 18039918
[TBL] [Abstract][Full Text] [Related]
9. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
10. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.
Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L
Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
12. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
[TBL] [Abstract][Full Text] [Related]
13. HSV shedding.
Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
Antiviral Res; 2004 Aug; 63 Suppl 1():S19-26. PubMed ID: 15450382
[TBL] [Abstract][Full Text] [Related]
14. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
Handsfield HH; Warren T; Werner M; Phillips JA
Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
[TBL] [Abstract][Full Text] [Related]
15. Genital shedding of herpes simplex virus among men.
Wald A; Zeh J; Selke S; Warren T; Ashley R; Corey L
J Infect Dis; 2002 Oct; 186 Suppl 1():S34-9. PubMed ID: 12353185
[TBL] [Abstract][Full Text] [Related]
16. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection.
Wald A; Carrell D; Remington M; Kexel E; Zeh J; Corey L
Clin Infect Dis; 2002 Apr; 34(7):944-8. PubMed ID: 11880960
[TBL] [Abstract][Full Text] [Related]
17. Helicase-primase inhibitor pritelivir for HSV-2 infection.
Wald A; Corey L; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Kriesel J; Fife K; Galitz L; Stoelben S; Huang ML; Selke S; Stobernack HP; Ruebsamen-Schaeff H; Birkmann A
N Engl J Med; 2014 Jan; 370(3):201-10. PubMed ID: 24428466
[TBL] [Abstract][Full Text] [Related]
18. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses.
Wu JJ; Huang DB; Tyring SK
Antiviral Res; 2004 Nov; 64(2):79-83. PubMed ID: 15498602
[TBL] [Abstract][Full Text] [Related]
19. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.
Bernstein DI; Harrison CJ; Tomai MA; Miller RL
J Infect Dis; 2001 Mar; 183(6):844-9. PubMed ID: 11237799
[TBL] [Abstract][Full Text] [Related]
20. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial.
Baeten JM; McClelland RS; Corey L; Overbaugh J; Lavreys L; Richardson BA; Wald A; Mandaliya K; Bwayo JJ; Kreiss JK
J Infect Dis; 2004 Apr; 189(8):1466-71. PubMed ID: 15073684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
